NCT06176495

Brief Summary

This is a Randomized Control Trial aiming at investigating the feasibility and effectiveness of a WhatsApp-based informative intervention on Diabetes Mellitus care in Lebanon and exploring the impact of this intervention on various aspects of Diabetes management and patient outcomes. Family member caregivers will be also included in this interventional study as the research investigators opt to evaluate their DM related knowledge, personal health practices, their involvement in the care of patients with diabetes, and their impact on the patients' diabetes control before and after the intervention.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P50-P75 for not_applicable diabetes-mellitus

Timeline
Completed

Started Jan 2024

Shorter than P25 for not_applicable diabetes-mellitus

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 21, 2023

Completed
28 days until next milestone

First Posted

Study publicly available on registry

December 19, 2023

Completed
13 days until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2024

Completed
Last Updated

January 5, 2024

Status Verified

December 1, 2023

Enrollment Period

10 months

First QC Date

November 21, 2023

Last Update Submit

January 3, 2024

Conditions

Keywords

Diabetes MellitusFamily Member CaregiversEducationEducational text messagesWhatsApp

Outcome Measures

Primary Outcomes (1)

  • Percentage change in glycemic control determined by HbA1C (in percent) in participants with diabetes pre and post intervention.

    To determine the effectiveness of diabetes tailored text messages on glycemic control in patients with diabetes mellitus, Percentage change in glycemic control determined by HbA1C (in percent) in participants with diabetes pre and post intervention will be assessed.

    at 3 and 6 months interval

Secondary Outcomes (8)

  • Change in knowledge before and after the intervention (in percentage)

    at 3 and 6 months interval

  • Changes in Daily Health Practices pre and post intervention (in percentage)

    at 3 and 6 months interval

  • Percentage change in weight (in Kg), height (in meters) and BMI (Kg/m2) pre and post intervention

    At 3 and 6 months interval

  • Percentage change in fasting sugar (mg/dl) pre and post intervention among participants with diabetes

    At 3 and 6 months interval

  • Percentage change in lipid profile composed of Total Cholesterol, LDL, HDL and Triglycerides ( all in mg/dl) among participants with diabetes pre and post intervention

    At 3 and 6 months interval

  • +3 more secondary outcomes

Study Arms (2)

Control Group

NO INTERVENTION

Patients with Diabetes and Family Member Caregivers who will receive no text messages over the designated period of the designated

Intervention Group

OTHER

Patients with Diabetes and Family Member Caregivers who will receive Educational Text Messages via WhatsApp over the designated period of the intervention

Diagnostic Test: Educational Text Messages

Interventions

The educational content will be targeted about Diabetes Education and will be guideline based with what complies to the standards of care instituted by the American Diabetes Association. They text messages will comprise content related to general diabetes knowledge, diabetes management and control, coping with diabetes, and guidance on adopting a healthy lifestyle.

Intervention Group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients 18 years or older
  • Patients with an established DM diagnosis
  • Patients with a recent HbA1c level with no recent changes in treatment regimen
  • Recent HbA1c \> 7 but less than 9
  • Patients who are on oral antidiabetic medications or basal insulin (intermediate, long acting, ultra long acting insulin)
  • Patients who are adherents to the American University of Beirut Health Insurance Plan (AUB-HIP)
  • Patients who have visited the Family Medicine Primary Care Clinics at American University of Beirut Clinics in the past 12 months.
  • Patients with smart mobile phones and/or access to WhatsApp services
  • Patients who can speak and read Arabic or English or live with someone who can read for them
  • Patients with available family members involved in their care (e.g. cooking, aiding in management, securing/delivering medications, having the patient medically insured, etc.).
  • Willingness to participate in the study

You may not qualify if:

  • Young patients below 18 years
  • Patients who are on non basal insulin/bolus therapy
  • Adults with cognitive impairment
  • Adults with functional dependence and no assisting family member or caregiver
  • Pregnant and Postpartum patients
  • Patients with terminal or critical diseases (e.g., cancer; advanced heart, lung, liver, and kidney disease; Human immunodeficiency virus infection and Acquired immune deficiency syndrome and etc.)
  • Patients with severe hearing or visual impairment
  • Patients who can't read or have difficulty reading and do not live with someone who can read for them
  • Patients who will have any of their medications modified throughout the study process will be excluded from the study as well
  • Patients with a positive depression (PHQ 2) and/or anxiety (GAD 2) screening results who will be asked to follow up with their primary physician
  • Age 18 years or older
  • Designated or selected by the participating patient with diabetes.
  • Not diagnosed with DM
  • Can read and write
  • No visual or hearing impairments
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (7)

  • Al-Mutawaa KA, Farghaly AH, Nasir R, Loares AM, Skaroni I, Al-Thani M, Abou-Samra AB. Level of knowledge, attitude and practice towards diabetes among nationals and long-term residents of Qatar: a cross-sectional study. BMJ Open. 2022 Feb 16;12(2):e052607. doi: 10.1136/bmjopen-2021-052607.

    PMID: 35172997BACKGROUND
  • Abaza H, Marschollek M. SMS education for the promotion of diabetes self-management in low & middle income countries: a pilot randomized controlled trial in Egypt. BMC Public Health. 2017 Dec 19;17(1):962. doi: 10.1186/s12889-017-4973-5.

  • Ernawati U, Wihastuti TA, Utami YW. Effectiveness of diabetes self-management education (DSME) in type 2 diabetes mellitus (T2DM) patients: Systematic literature review. J Public Health Res. 2021 Apr 14;10(2):2240. doi: 10.4081/jphr.2021.2240.

  • Karaoui LR, Deeb ME, Nasser L, Hallit S. Knowledge and practice of patients with diabetes mellitus in Lebanon: a cross-sectional study. BMC Public Health. 2018 Apr 20;18(1):525. doi: 10.1186/s12889-018-5416-7.

  • Sahin C, Courtney KL, Naylor PJ, E Rhodes R. Tailored mobile text messaging interventions targeting type 2 diabetes self-management: A systematic review and a meta-analysis. Digit Health. 2019 Apr 22;5:2055207619845279. doi: 10.1177/2055207619845279. eCollection 2019 Jan-Dec.

  • Bin Abbas B, Al Fares A, Jabbari M, El Dali A, Al Orifi F. Effect of mobile phone short text messages on glycemic control in type 2 diabetes. Int J Endocrinol Metab. 2015 Jan 1;13(1):e18791. doi: 10.5812/ijem.18791. eCollection 2015 Jan.

  • Omar MA, Hasan S, Palaian S, Mahameed S. The impact of a self-management educational program coordinated through WhatsApp on diabetes control. Pharm Pract (Granada). 2020 Apr-Jun;18(2):1841. doi: 10.18549/PharmPract.2020.2.1841. Epub 2020 May 3.

Related Links

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Najla El Lakkis, FAM MED

    American University of Beirut Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Najla El Lakkis, FAM MED

CONTACT

Farah Farhat, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Specialist in Family Medicine; Specialist in Occupational Medicine; Clinical Associate in Family Medicine

Study Record Dates

First Submitted

November 21, 2023

First Posted

December 19, 2023

Study Start

January 1, 2024

Primary Completion

November 1, 2024

Study Completion

November 1, 2024

Last Updated

January 5, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share